NO160137C - Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner.

Info

Publication number
NO160137C
NO160137C NO813804A NO813804A NO160137C NO 160137 C NO160137 C NO 160137C NO 813804 A NO813804 A NO 813804A NO 813804 A NO813804 A NO 813804A NO 160137 C NO160137 C NO 160137C
Authority
NO
Norway
Prior art keywords
pyrimidines
diamino
substituted
preparation
therapeutic active
Prior art date
Application number
NO813804A
Other languages
English (en)
Other versions
NO160137B (no
NO813804L (no
Inventor
Susan Mary Daluge
Paul Marcel Skonezny
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO813804L publication Critical patent/NO813804L/no
Publication of NO160137B publication Critical patent/NO160137B/no
Publication of NO160137C publication Critical patent/NO160137C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO813804A 1980-11-11 1981-11-10 Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner. NO160137C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8036135 1980-11-11

Publications (3)

Publication Number Publication Date
NO813804L NO813804L (no) 1982-05-12
NO160137B NO160137B (no) 1988-12-05
NO160137C true NO160137C (no) 1989-03-15

Family

ID=10517217

Family Applications (2)

Application Number Title Priority Date Filing Date
NO813804A NO160137C (no) 1980-11-11 1981-11-10 Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner.
NO1994029C NO1994029I1 (no) 1980-11-11 1994-12-29 Baquiloprim/ 2,4-diamino-5-(8-dimetylamino-7-metyl-5-kinolylmetyl)pyrimidin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1994029C NO1994029I1 (no) 1980-11-11 1994-12-29 Baquiloprim/ 2,4-diamino-5-(8-dimetylamino-7-metyl-5-kinolylmetyl)pyrimidin

Country Status (35)

Country Link
US (4) US4438267A (no)
EP (1) EP0051879B1 (no)
JP (1) JPS57114581A (no)
KR (1) KR880001736B1 (no)
AR (1) AR245447A1 (no)
AU (1) AU549449B2 (no)
CA (1) CA1186310A (no)
CS (1) CS273153B2 (no)
CY (1) CY1419A (no)
DD (1) DD201896A5 (no)
DE (1) DE3173752D1 (no)
DK (1) DK172884B1 (no)
EG (1) EG16107A (no)
ES (5) ES506969A0 (no)
FI (1) FI76333C (no)
GB (1) GB2087881B (no)
GR (1) GR81317B (no)
HK (1) HK23388A (no)
HU (1) HU188762B (no)
IE (1) IE52128B1 (no)
IL (1) IL64256A (no)
IT (1) IT1210589B (no)
MC (1) MC1418A1 (no)
MY (1) MY8600678A (no)
NO (2) NO160137C (no)
NZ (1) NZ198932A (no)
PH (2) PH22654A (no)
PL (4) PL139427B1 (no)
PT (1) PT73960B (no)
RU (1) RU1819264C (no)
SG (1) SG62686G (no)
SU (4) SU1424732A3 (no)
YU (5) YU42444B (no)
ZA (1) ZA817780B (no)
ZM (1) ZM9481A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438267A (en) * 1980-11-11 1984-03-20 Daluge Susan M Monoheteroring compounds and their use
ZA833067B (en) * 1982-05-01 1984-12-24 Wellcome Found Antibacterial compounds
DK190983A (da) * 1982-05-01 1983-11-02 Wellcome Found 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor
US4590271A (en) * 1982-05-01 1986-05-20 Burroughs Wellcome Co. 2,4-diamino-5-(substituted)pyrimidines, useful as antimicrobials
US4587341A (en) * 1982-05-07 1986-05-06 Burroughs Wellcome Co. 2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials
CA1244028A (en) * 1983-04-14 1988-11-01 Hans Maag Pyrimidine derivatives
GB8603962D0 (en) * 1986-02-18 1986-03-26 Wellcome Found Chemical compositions
GB8603964D0 (en) * 1986-02-18 1986-03-26 Cooper Animal Health Ltd Compositions
LU86703A1 (fr) * 1986-12-08 1988-07-14 Oreal Composition cosmetique photostable contenant un filtre uv-a et un filtre uv-b,son utilisation pour la protection de la peau contre les rayons uv et procede de stabilisation du filtre uv-a par le filtre uv-b
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
GB8903978D0 (en) * 1989-02-22 1989-04-05 Coopers Animal Health Chemical compositions
GB9000241D0 (en) * 1990-01-05 1990-03-07 Coopers Animal Health Pharmaceutical use
RU95113597A (ru) * 1992-12-02 1997-06-10 ФМК Корпорейшн (US) Инсектицидная композиция, способы борьбы с насекомыми
US5707996A (en) * 1995-11-06 1998-01-13 Macleod Pharmaceuticals, Inc. Pharmaceutical solution and methods for preparation thereof
JP3309340B2 (ja) * 1995-12-04 2002-07-29 アルピダ・アーゲー ジアミノピリミジン、それらを含む医薬組成物及びそれらの抗菌剤としての用途
WO2002010156A1 (en) * 2000-07-29 2002-02-07 Arpida Ag Benzofuran derivatives and their use as antibacterial agents
DE60216281T2 (de) * 2001-06-29 2007-07-05 Ab Science Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
WO2003002108A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
US7727731B2 (en) * 2001-06-29 2010-06-01 Ab Science Potent, selective and non toxic c-kit inhibitors
JP2004537542A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
WO2003035050A2 (en) * 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
EP1427379B1 (en) * 2001-09-20 2008-08-13 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
WO2003035049A2 (en) * 2001-09-20 2003-05-01 Ab Science Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
JP2009513524A (ja) * 2003-07-11 2009-04-02 アルパイダ アーゲー 新規ベンゾフラン誘導体
EP1856109A1 (en) * 2005-02-18 2007-11-21 Arpida AG Novell processes for the preparation of a benzofuran
ES2601178T3 (es) * 2005-09-01 2017-02-14 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P3X2/3
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20120122819A1 (en) * 2009-06-12 2012-05-17 Socpra - Sciences Et Genie S.E.C. Guanine riboswitch binding compounds and their use as antibiotics
CN102649786B (zh) * 2011-02-28 2014-08-27 郑州福源动物药业有限公司 一种2，4-二氨基-5-(8-二甲氨基-7-甲基-5-喹啉基甲基)-2，4-(1h，3h)嘧啶的制备方法
CN103755684B (zh) * 2014-02-10 2015-09-09 青岛蔚蓝生物股份有限公司 一种巴喹普林的制备方法
US20220332714A1 (en) * 2019-06-06 2022-10-20 Beijing Tide Pharmaceutical Co., Ltd. P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof
CN110818694B (zh) * 2019-11-18 2023-04-21 上海医药工业研究院有限公司 艾拉普林中间体及其应用
WO2022217295A1 (en) * 2021-04-09 2022-10-13 The Trustees Of The University Of Pennsylvania Control of protein expression with tmp-protac compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3049544A (en) * 1962-08-14 Method for the preparation of
DE1303727B (de) 1959-09-03 1976-02-05 Ausscheidung aus: 14 45 176 The Wellcome Foundation Ltd., London Alpha-Arylidensubstituierte Propioni-Irile
US3956327A (en) * 1969-03-06 1976-05-11 Burroughs Wellcome Co. Method of preparing 2,4-diamino-5-benzyl pyrimidines
BE792096A (fr) * 1971-12-01 1973-05-30 Hoffmann La Roche Nouvelles benzylpyrimidines
GB1468374A (en) 1974-03-06 1977-03-23 Wellcome Found Process for preparing a pyrimidine derivative
US4039543A (en) 1974-12-24 1977-08-02 Hoffmann-La Roche Inc. Benzylpyrimidines
GB1582245A (en) * 1976-06-09 1981-01-07 Wellcome Found Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives
DE2730467A1 (de) * 1977-07-06 1979-01-18 Basf Ag Benzylpyrimidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4258045A (en) * 1979-11-30 1981-03-24 Merck & Co., Inc. Inhibitor of dihydrofolate reductase
US4438267A (en) * 1980-11-11 1984-03-20 Daluge Susan M Monoheteroring compounds and their use

Also Published As

Publication number Publication date
ES521204A0 (es) 1984-06-01
ES521202A0 (es) 1984-06-01
GB2087881A (en) 1982-06-03
YU42444B (en) 1988-08-31
ZA817780B (en) 1983-06-29
NO160137B (no) 1988-12-05
ZM9481A1 (en) 1983-11-21
GR81317B (no) 1984-12-11
YU198283A (en) 1984-04-30
GB2087881B (en) 1985-05-15
US4438267A (en) 1984-03-20
IE812631L (en) 1982-05-11
DE3173752D1 (en) 1986-03-20
YU198183A (en) 1984-04-30
CS825781A2 (en) 1990-07-12
NZ198932A (en) 1985-05-31
ES8405377A1 (es) 1984-06-01
PT73960B (en) 1983-11-23
DK172884B1 (da) 1999-09-06
CY1419A (en) 1988-04-22
YU266381A (en) 1984-04-30
ES521201A0 (es) 1984-06-01
ES8307759A1 (es) 1983-07-01
PL233754A1 (en) 1983-08-01
FI76333C (fi) 1988-10-10
DK496681A (da) 1982-05-12
IL64256A0 (en) 1982-02-28
PT73960A (en) 1981-12-01
EP0051879A3 (en) 1982-08-04
MC1418A1 (fr) 1982-10-18
KR830007628A (ko) 1983-11-04
PL239280A1 (en) 1983-08-01
IL64256A (en) 1988-01-31
US4587342A (en) 1986-05-06
PL139427B1 (en) 1987-01-31
SU1306473A3 (ru) 1987-04-23
KR880001736B1 (ko) 1988-09-10
AU7733481A (en) 1982-05-20
CA1186310A (en) 1985-04-30
HU188762B (en) 1986-05-28
SU1535379A3 (ru) 1990-01-07
PH25053A (en) 1991-01-28
US4603136A (en) 1986-07-29
JPH0474351B2 (no) 1992-11-26
ES8405379A1 (es) 1984-06-01
SU1318148A3 (ru) 1987-06-15
MY8600678A (en) 1986-12-31
ES521203A0 (es) 1984-06-01
IE52128B1 (en) 1987-06-24
NO813804L (no) 1982-05-12
JPS57114581A (en) 1982-07-16
ES8405380A1 (es) 1984-06-01
YU46697B (sh) 1994-04-05
PH22654A (en) 1988-10-28
FI76333B (fi) 1988-06-30
PL139828B1 (en) 1987-02-28
SU1424732A3 (ru) 1988-09-15
YU144288A (en) 1990-04-30
PL139827B1 (en) 1987-02-28
US4761475A (en) 1988-08-02
PL139523B1 (en) 1987-01-31
IT8149676A0 (it) 1981-11-10
EG16107A (en) 1987-10-30
EP0051879A2 (en) 1982-05-19
HK23388A (en) 1988-04-08
YU198383A (en) 1984-04-30
AU549449B2 (en) 1986-01-30
FI813546L (fi) 1982-05-12
IT1210589B (it) 1989-09-14
YU43551B (en) 1989-08-31
PL239279A1 (en) 1983-08-01
SG62686G (en) 1987-03-27
NO1994029I1 (no) 1994-12-29
PL239278A1 (en) 1983-08-01
EP0051879B1 (en) 1986-02-05
ES8405378A1 (es) 1984-06-01
RU1819264C (ru) 1993-05-30
ES506969A0 (es) 1983-07-01
CS273153B2 (en) 1991-03-12
DD201896A5 (de) 1983-08-17
AR245447A1 (es) 1994-01-31

Similar Documents

Publication Publication Date Title
NO160137C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner.
NO156785C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklobutan-derivater.
NO158419C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,2-diaminocyklobuten-3,4-dioner.
NO164025C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-imidazolylmetyl-tetrahydrokarbazolon-derivater.
NO154918C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
NO160850C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-(bicykliske heterocyklyl)-4-piperidinaminer.
NO150760C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotiazoler.
NO166367C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tieno-1,4-diazepiner.
NO161497C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 9a-aza-9a-homoerytromycin-derivater.
NO154492C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme forbindelser.
NO164541C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater.
NO158460C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO871044D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrimidinderivater.
NO155665C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6,7,7a-tetrahydro-4h-thieno-(3,2-c)-pyridin-2-on-derivater.
NO152649C (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive fenylalkylaminer.
NO160370C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive penam-1,1-dioksyd-forbindelser.
NO153137C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte pyrido(1,2-a)pyrimidiner.
NO159090C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater.
NO873680D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfonamido-etyl-forbindelser.
NO156167C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolinon-derivater.
NO158800C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indenderivater.
NO163570C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive acylaminomitosaner.
NO162188C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinoliner.
NO881768D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner.
NO152843C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidopyrimidiner.

Legal Events

Date Code Title Description
MK1K Patent expired

Free format text: EXPIRED IN NOVEMBER 2001